Centre for Global Health and Health Partnerships, King's College London, London, United Kingdom.
Department of Anesthesia, Great Ormond Street Hospital, London, United Kingdom.
Ann Surg. 2022 May 1;275(5):1018-1024. doi: 10.1097/SLA.0000000000004498. Epub 2020 Sep 15.
To evaluate the economic case for nationwide scale-up of the World Health Organization (WHO) Surgical Safety Checklist using cost-effectiveness and benefit-cost analyses.
The Checklist improves surgical outcomes but the economic case for widespread use remains uncertain. For perioperative quality improvement interventions to compete successfully against other worthwhile health and nonhealth interventions for limited government resources they must demonstrate cost-effectiveness and positive societal benefit.
Using data from 3 countries, we estimated the benefits as the total years of life lost (YLL) due to postoperative mortality averted over a 3 year period; converted the benefits to dollar equivalent values using estimates of the economic value of an additional year of life expectancy; estimated total implementation costs; and determined incremental cost-effectiveness ratio (ICER) and benefit-cost ratio (BCR). Costs are reported in international dollars using Word Bank purchasing power parity conversion factors at 2016 price-levels.
In Benin, Cameroon, and Madagascar ICERs were: $31, $138, and $118 per additional YLL averted; and BCRs were 62, 29, and 9, respectively. Sensitivity analysis demonstrated that the associated mortality reduction and increased usage due to Checklist scale-up would need to deviate approximately 10-fold from published data to change our main interpretations.
According to WHO criteria, Checklist scale-up is considered "very cost-effective" and for every $ 1 spent the potential return on investment is $9 to $62. These results compare favorably with other health and nonhealth interventions and support the economic argument for investing in Checklist scale-up as part of a national strategy for improving surgical outcomes.
通过成本效益和收益成本分析,评估世界卫生组织(WHO)手术安全检查表在全国范围内扩大规模的经济情况。
检查表可改善手术结果,但广泛使用的经济案例仍不确定。对于围手术期质量改进干预措施来说,要想在有限的政府资源范围内与其他有价值的卫生和非卫生干预措施竞争,就必须证明其具有成本效益和积极的社会效益。
使用来自 3 个国家的数据,我们将术后死亡率降低导致的总生命年损失(YLL)估计为 3 年内避免的 YLL;将效益转换为美元等值,使用预期的额外预期寿命的经济价值估算;估计总成本;并确定增量成本效益比(ICER)和收益成本比(BCR)。成本以国际元为单位报告,使用世界银行购买力平价转换因素按 2016 年的价格水平计算。
在贝宁、喀麦隆和马达加斯加,ICER 分别为:每避免额外 YLL 增加 31 美元、138 美元和 118 美元;BCR 分别为 62、29 和 9。敏感性分析表明,由于检查表的扩大规模而导致的死亡率降低和使用量增加,需要与已发表的数据相差约 10 倍,才能改变我们的主要解释。
根据世卫组织的标准,检查表的扩大规模被认为是“非常具有成本效益的”,每投资 1 美元,潜在投资回报率为 9 美元至 62 美元。这些结果与其他卫生和非卫生干预措施相比具有优势,并支持将检查表扩大规模作为改善手术结果的国家战略的一部分进行投资的经济论点。